Evidence map›Paper›PMID 31293417›Full record

ArticleFrontiers in pharmacology2019

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx

Manuela Robella, Marco Vaira, Monica Argenziano, Rita Spagnolo, Roberta Cavalli, Alice Borsano, Sergio Gentilli, Michele De Simone

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Manuela RobellaUnit of Surgical Oncology, Candiolo Cancer Institute, IRCCS-FPO, Candiolo, Italy.
Marco VairaUnit of Surgical Oncology, Candiolo Cancer Institute, IRCCS-FPO, Candiolo, Italy.
Monica ArgenzianoDepartment of Drug Science and Technology, University of Torino, Torino, Italy.
Rita SpagnoloDepartment of Drug Science and Technology, University of Torino, Torino, Italy.
Roberta CavalliDepartment of Drug Science and Technology, University of Torino, Torino, Italy.
Alice BorsanoDepartment of Drug Science and Technology, University of Torino, Torino, Italy.
Sergio GentilliGeneral Surgery Unit, Department of Health Science, University of Eastern Piedmont, Novara, Italy.
Michele De SimoneUnit of Surgical Oncology, Candiolo Cancer Institute, IRCCS-FPO, Candiolo, Italy.
University of Turin · ITCandiolo Cancer Institute · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

doxorubicinlocoregional chemotherapypegylated liposomesperitoneal carcinomatosisPIPAC

Identifiers

PMID31293417
PMCPMC6603215
OpenAlexW2956048430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.